Loading...
Loading...
ORGO| Name | Value |
|---|---|
| Revenues | 130.2M |
| Cost of Revenue | 33.6M |
| Gross Profit | 96.6M |
| Operating Expense | 92.1M |
| Operating I/L | -13.9M |
| Other Income/Expense | -0.6M |
| Interest Income | 0.0M |
| Pretax | -14.5M |
| Income Tax Expense | 2.5M |
| Net Income/Loss | -17.0M |
Organogenesis Holdings Inc. is a regenerative medicine company that develops, manufactures, and commercializes advanced wound care and surgical and sports medicine solutions in the United States. The company's products include advanced wound care solutions such as Affinity, Apligraf, Dermagraft, NuShield, PuraPly, and Novachor, as well as surgical and sports medicine products like NuCel, ReNu, FiberOS, and OCMP. These products are sold to hospitals, wound care centers, government facilities, ambulatory service centers, and physician offices through a direct sales force and independent agencies, generating revenue through the sale of these regenerative medicine products.
